SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sip...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassinello, J., Arranz, J. Á., Piulats, J. M., Sánchez, A., Pérez-Valderrama, B., Mellado, B., Climent, M. Á., Olmos, D., Carles, J., Lázaro, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Clinical Guides in Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785604/
https://www.ncbi.nlm.nih.gov/pubmed/29134562
http://dx.doi.org/10.1007/s12094-017-1783-2
Descripción
Sumario:Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.

Ejemplares similares